u-75302 and Pulmonary-Disease--Chronic-Obstructive

u-75302 has been researched along with Pulmonary-Disease--Chronic-Obstructive* in 2 studies

Other Studies

2 other study(ies) available for u-75302 and Pulmonary-Disease--Chronic-Obstructive

ArticleYear
Cigarette smoke-induced lung inflammation in COPD mediated via LTB4/BLT1/SOCS1 pathway.
    International journal of chronic obstructive pulmonary disease, 2016, Volume: 11

    Evidence suggests that suppressor of cytokine signaling 1 (SOCS1) is crucial for the negative regulation of inflammation. We investigated the relationship between smoking, SOCS1, and leukotriene B4 (LTB4) in vitro and in clinical samples of COPD; besides which we detected the impact of LTB4 receptor 1 (BLT1) antagonist on inflammation.. SOCS1 expression in bronchial mucosa was determined by immunohistochemistry and real-time polymerase chain reaction. We also detect SOCS1 and BLT1 expression in alveolar macrophages from bronchoalveolar lavage fluid (BALF) by real time-PCR, in addition to measuring the level of cytokines in BALF using enzyme-linked immunosorbent assay. In vitro, we investigated the expression of SOCS1 in cigarette smoke extract-induced mouse macrophage cell line RAW264.7 by real-time polymerase chain reaction and Western blot, and detected the level of cytokines in the supernatant by enzyme-linked immunosorbent assay. Then, we investigated the effects of BLT1 antagonist U-75302 on SOCS1 expression in these cells.. We obtained endobronchial biopsies (15 COPD patients and 12 non-COPD control subjects) and BALF (20 COPD patients and 20 non-COPD control subjects), and our results showed that SOCS1 expression significantly decreased in lung tissues from COPD patients. Inflammatory cytokines in BALF were higher in COPD and these inflammatory cytokines negatively correlate with SOCS1 levels. Further, the BLT1 antagonist restored SOCS1 expression and in turn inhibited inflammatory cytokine secretion in vitro.. Long-term cigarette smoke exposure induced SOCS1 degradation and LTB4 accumulation, which was associated with emphysema and inflammation. A BLT1 antagonist might be a potential therapeutic candidate for the treatment of COPD.

    Topics: Aged; Animals; Bronchoalveolar Lavage Fluid; Fatty Alcohols; Female; Glycols; Humans; Immunohistochemistry; Leukotriene B4; Male; Mice; Middle Aged; Pneumonia; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Receptors, Leukotriene B4; Respiratory Mucosa; Signal Transduction; Smoking; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins

2016
Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD.
    Chest, 2009, Volume: 136, Issue:4

    Neutrophils have been implicated in the pathogenesis of COPD. Several chemoattractants for neutrophils have been measured in samples of exhaled breath condensate (EBC) and induced sputum (IS) from patients with COPD. The aims of this study were to compare EBC and IS supernatant neutrophil chemotactic activity (NCA) from ex-smoking subjects with COPD and healthy ex-smokers, and to assess the contribution of leukotriene B(4) (LTB(4)) to this activity.. Thirty-four subjects with COPD were compared to 24 control subjects. EBC and IS chemotactic activity for neutrophils was assessed by using Boyden microchambers. The chemotactic index was used to evaluate cell migration. LTB(4) was measured by a specific enzyme immunoassay. The contribution of LTB(4) to EBC and sputum neutrophil chemotaxis was assessed by an LTB(4) receptor antagonist (U-75302; Cayman Chemical Company; Ann Arbor, MI).. EBC and IS samples from both COPD patients and healthy subjects displayed significant NCA, but this activity was raised in COPD patients compared to healthy subjects. The chemotactic activity contained in sputum, however, failed to correlate with that in EBC. In COPD patients, there was a significant correlation between EBC NCA and sputum neutrophil counts. LTB(4) levels were raised in EBC samples, but not in sputum samples, from COPD subjects compared to those from healthy subjects. LTB(4) receptor antagonist concentrations (2.5 x 10(-4) mol/L) reduced by 44.6% and by 44.4%, respectively, the chemotactic activity contained in the EBC and sputum samples.. EBC and IS from COPD patients have a raised NCA to which LTB(4) contributes.

    Topics: Breath Tests; Chemotaxis, Leukocyte; Exhalation; Fatty Alcohols; Glycols; Humans; Immunoenzyme Techniques; Leukotriene B4; Neutrophils; Pulmonary Disease, Chronic Obstructive; Sputum

2009